Joerger M - Search Results

1

Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study.

Joerger M, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-Marsico J, Diem S, Thuerlimann B, Cerny T. Joerger M, et al. Eur J Clin Pharmacol. 2014 Jun;70(6):719-25. doi: 10.1007/s00228-014-1662-5. Epub 2014 Mar 11. Eur J Clin Pharmacol. 2014. PMID: 24609468

2

Postradiation high-grade myofibroblastic sarcoma of the prostate -- a rare entity of prostatic tumors -- responding to liposomal Doxorubicin.

Joerger M, Oehlschlegel C, Cerny T, Gillessen S. Joerger M, et al. Onkologie. 2002 Dec;25(6):558-61. doi: 10.1159/000068628. Onkologie. 2002. PMID: 12566902

3

Von Hippel-Lindau disease--a rare disease important to recognize.

Joerger M, Koeberle D, Neumann HP, Gillessen S. Joerger M, et al. Onkologie. 2005 Mar;28(3):159-63. doi: 10.1159/000083860. Onkologie. 2005. PMID: 15772467 Review.

4

A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma.

Jermann M, Stahel RA, Salzberg M, Cerny T, Joerger M, Gillessen S, Morant R, Egli F, Rhyner K, Bauer JA, Pless M. Jermann M, et al. Among authors: joerger m. Cancer Chemother Pharmacol. 2006 Apr;57(4):533-9. doi: 10.1007/s00280-005-0070-z. Epub 2005 Jul 29. Cancer Chemother Pharmacol. 2006. PMID: 16052341 Free article. Clinical Trial.

5

Hypertriglyceridemia as a possible risk factor for prostate cancer.

Wuermli L, Joerger M, Henz S, Schmid HP, Riesen WF, Thomas G, Krek W, Cerny T, Gillessen S. Wuermli L, et al. Among authors: joerger m. Prostate Cancer Prostatic Dis. 2005;8(4):316-20. doi: 10.1038/sj.pcan.4500834. Prostate Cancer Prostatic Dis. 2005. PMID: 16158078

6

Increased pulmonary FDG uptake in bleomycin-associated pneumonitis.

von Rohr L, Klaeser B, Joerger M, Kluckert T, Cerny T, Gillessen S. von Rohr L, et al. Among authors: joerger m. Onkologie. 2007 Jun;30(6):320-3. doi: 10.1159/000101517. Epub 2007 May 29. Onkologie. 2007. PMID: 17551256

7

Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study.

Joerger M, Huitema AD, Huizing MT, Willemse PH, de Graeff A, Rosing H, Schellens JH, Beijnen JH, Vermorken JB. Joerger M, et al. Br J Clin Pharmacol. 2007 Nov;64(5):622-33. doi: 10.1111/j.1365-2125.2007.02956.x. Br J Clin Pharmacol. 2007. PMID: 17935602 Free PMC article.

8

CT-diagnosed mesenteric alterations in patients with non-Hodgkin's lymphoma: a population-based study.

Joerger M, Nuessli DF, Henz S, Zaunbauer W, Cerny T, Cogliatti SB, Gillessen S. Joerger M, et al. Onkologie. 2008 Oct;31(10):514-9. doi: 10.1159/000151624. Epub 2008 Sep 23. Onkologie. 2008. PMID: 18854650

9

The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action.

Joerger M, Omlin A, Cerny T, Früh M. Joerger M, et al. Curr Drug Targets. 2010 Jan;11(1):37-47. doi: 10.2174/138945010790030974. Curr Drug Targets. 2010. PMID: 19839929 Review.

10

Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial.

Joerger M, Huitema AD, Krähenbühl S, Schellens JH, Cerny T, Reni M, Zucca E, Cavalli F, Ferreri AJ. Joerger M, et al. Br J Cancer. 2010 Feb 16;102(4):673-7. doi: 10.1038/sj.bjc.6605559. Epub 2010 Feb 2. Br J Cancer. 2010. PMID: 20125159 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

181 results

Search Page

Filters